Blackmores grows with Impromy range
This article was originally published in OTC Bulletin & The Rose Sheet
Australia’s Blackmores is poised to expand its portfolio by acquiring the Impromy range of weight-management products for AU$9.0 million (€5.9 million). The deal is slated to close in November 2018 and is expected to be earnings accretive in the first year.
You may also be interested in...
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.